THE MOBILE INSULIN TITRATION INTERVENTION PROGRAM TO TRANSITION FROM BASAL INSULIN TO A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (MITI-GLP1): USING DAILY SMS TEXT MESSAGES AND WEEKLY PHONE CALLS TO TRANSITION PRIMARY CARE PATIENTS WITH WELL-CONTROLLED TYPE 2 DIABETES FROM BASAL INSULIN TO A GLP1-RA

被引：0
|
作者：
Levy, Natalie K. [1 ]
Nerlino, Katie [1 ]
Bongalos, Sherlane B. [2 ]
Dasilva, Alexis [2 ]
Uzor, Chinye N. [2 ]
Sonubi, Olubunmi O. [2 ]
机构：
[1] NYU, Bellevue Hosp, Med, Sch Med, New York, NY USA
[2] Bellevue Hosp Ctr, Med, New York, NY USA
来源：
JOURNAL OF GENERAL INTERNAL MEDICINE | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：S637 / S637
页数：1
相关论文
共 46 条
  • [1] The Mobile Insulin Titration Intervention to Transition from Basal Insulin to a GLP1-RA (MITI-GLP1)-Using Daily SMS Text Messages and Weekly Phone Calls to Transition Primary Care Patients with Well-Controlled Type 2 Diabetes Mellitus from Basal Insulin to a GLP1-RA at Bellevue Hospital
    Levy, Natalie
    Nerlino, Katie
    Sonubi, Olubunmi
    Bongalos, Sherlane
    Dasilva, Alex
    Uzor, Chinye
    Liang, Yingjie
    DIABETES, 2024, 73
  • [2] Efficacy and safety of Glucagon-like peptide-1 receptor agonist (GLP-1RA) plus basal insulin versus basal insulin in Type 2 Diabetes Mellitus: A Systematic review and Meta-analysis
    Conboy, M.
    Houlihan, C.
    O'Brien, T.
    Liew, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S372 - S372
  • [3] Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes
    Mehta, Roopa
    Billings, Liana K.
    Liebl, Andreas
    Vilsboll, Tina
    DIABETIC MEDICINE, 2022, 39 (09)
  • [4] Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy
    Shubrook, Jay H.
    JOURNAL OF FAMILY PRACTICE, 2018, 67 (08): : S49 - S54
  • [5] Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus-A Systematic Review and Meta-analysis
    Satti, Muniza M.
    O'Brien, Timothy
    Liew, Aaron
    DIABETES, 2018, 67
  • [6] Efficacy and safety of IDegLira (combination of insulin degludec and liraglutide) in insulin-naive patients with Type 2 diabetes inadequately controlled on glucagon-like peptide-1 receptor agonist(GLP-1RA) therapy
    Viljoen, A.
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J-P
    Handelsman, Y.
    Lehmann, L. M.
    Mishra, A.
    Simpson, R. W.
    DIABETIC MEDICINE, 2016, 33 : 63 - 64
  • [7] In insulin-naive patients with Type 2 diabetes inadequately controlled on a glucagon-like peptide-1 receptor agonist (GLP-1RA), IDegLira (combination of insulin degludec and liraglutide) resulted in improved patient-reported outcomes vs unchanged GLP-1RA
    Russell-Jones, D.
    Brod, M.
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J. P.
    Handelsman, Y.
    Kongso, J. H.
    Reiter, P. D.
    Simpson, R. W.
    DIABETIC MEDICINE, 2016, 33 : 68 - 68
  • [8] Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
    Fazeli, Sasan
    Ehrhardt, Nicole
    DIABETES, 2018, 67
  • [9] Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis
    Lin, Kaiping
    Lv, Qi
    Yang, Xiaoling
    Lin, Ting
    Feng, Min
    Chen, Xiaxia
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (10) : 2213 - 2217
  • [10] Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks
    Leiter, Lawrence A.
    Gross, Jorge Luiz
    Chow, Francis
    Miller, Diane
    Johnson, Susan
    Ahren, Bo
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (08) : 1283 - 1285
12345